联系方式
联系电话：13641103617
所在单位：河南省医学科学院肿瘤研究所、中国医学科学院肿瘤医院、分子肿瘤学全国重点实验室
个人简介
1983-1987 年：北京大学 细胞生物学专业理学学士
1987-1990 年：中国农业大学 分子遗传学专业理学硕士
1990-1993 年：北京大学 植物基因工程及蛋白质工程国家重点实验室 植物生理学专业 理学博士
1993-1996 年：美国华盛顿州立大学 博士后
1996-2000 年：中国医学科学院肿瘤医院 副研究员
2000 年 - 今：中国医学科学院肿瘤医院 研究员、博士生导师
2016-2018 年：中国医学科学院肿瘤医院 院长助理
2018 年 - 今：分子肿瘤学国家重点实验室 主任；中国医学科学院肿瘤医院 副院长
2023 年 - 今：国家癌症中心 副主任
2024 年 - 今：河南省医学科学院肿瘤研究所
学术兼职：分子肿瘤学国家重点实验室学术委员会委员、中国抗癌协会肿瘤病因学专业委员会荣誉主任委员、中国细胞生物学会肿瘤细胞生物学分会副会长等；《Journal of the National Cancer Center》《中国癌症杂志》等多个核心期刊副主编 / 编委。
Personal Profile
1983-1987: Peking University Bachelor of Science in Cell Biology
1987-1990: China Agricultural University Master of Science
1990-1993: Peking University, State Key Laboratory of Plant Genetic Engineering and Protein Engineering Doctor of Science in Plant Physiology
1993-1996: Washington State University, USA Postdoctoral Fellow
1996-2000: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences Associate Researcher
2000- : National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences Researcher, Doctoral Supervisor
2016-2018: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences Assistant to the President
2018- : State Key Laboratory of Molecular Oncology Director; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences Vice President
2023- : National Cancer Center Deputy Director
2024- : Henan Academy of Medical Sciences, Cancer Research Institute DirectorAcademic Affiliations: Member of the Academic Committee of State Key Laboratory of Molecular Oncology, Honorary Chairman of the Etiology Committee of Chinese Anti-Cancer Association, Vice Chairman of the Cancer Cell Biology Branch of Chinese Society for Cell Biology, etc.; Associate Editor/Editorial Board Member of journals including 《Journal of the National Cancer Center》and 《Chinese Journal of Cancer》.
研究方向和领域
肿瘤生物学、计算生物学与生物信息学
Cancer Biology, Computational Biology and Bioinformatics
研究内容
专注肿瘤异质性与精准诊疗研究，构建食管癌“四分型” 体系并制定亚型专属治疗策略，研发3 套早诊标志物并推进专利转化；从表观遗传异常、蛋白质稳态失衡等视角解析瘤内异质性驱动机制，发掘 AR、Homeobox 等新靶点；结合多组学及单细胞分析，鉴定免疫治疗疗效预测标志物，优化免疫联合治疗方案，构建 “分型 - 诊断 - 治疗 - 监测” 精准诊疗体系，助力恶性肿瘤诊疗水平提升。
Research Interests
Prof. Liu focuses on cancer heterogeneity and precision diagnosis/treatment. She established a four-subtype classification system for esophageal cancer with subtype-specific therapeutic strategies, developed 3 sets of early diagnostic biomarkers and promoted their patent transformation. She deciphers the driving mechanisms of intratumoral heterogeneity from perspectives such as epigenetic abnormalities and protein homeostasis imbalance, identifying novel targets like AR and Homeobox. Integrating multi-omics and single-cell analyses, she identifies predictive biomarkers for immunotherapy efficacy, optimizes combined immunotherapy regimens, and constructs a classification-diagnosis-treatment-monitoring precision medical system to improve the diagnosis and treatment of malignant tumors.
研究成果 (about 10)
1. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell. 41(1):181-195. 2023. Q1, IF=48.8. Liu Zhihua* (Corresponding Author)
2. Distinct cellular mechanisms underlie chemotherapies and their combinations with PD-L1 checkpoint inhibitor in triple-negative breast cancer. Cancer Cell. 43:446-463. 2025.3. Q1, IF=48.8. Liu Zhihua*
3. Progenitor-like exhausted SPRY1+ CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer Cell. 41(11):1852-1870. 2023.11. Q1, IF=48.8. Liu Zhihua*
4. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 39(12):1578-1593. 2021.12. Q1, IF=48.8. Liu Zhihua*
5. Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response. Signal Transduction and Targeted Therapy. 10(1):348. 2025.10. Q1, IF=52.7. Liu Zhihua*
6. Multimodal analysis of cfDNA methylomes for early detecting esophageal squamous cell carcinoma and precancerous lesions. Nature Communications. 15(1):3700. 2024.5. Q1, IF=14.7. Liu Zhihua*
7. The transcriptional landscape and diagnostic potential of long non-coding RNAs in esophageal squamous cell carcinoma. Nature Communications. 14:3799. 2023.6. Q1, IF=14.7. Liu Zhihua*
8. RPS15 interacted with IGF2BP1 to promote esophageal squamous cell carcinoma development via recognizing m6A modification. Signal Transduction and Targeted Therapy. 8(1):224. 2023.6. Q1, IF=40.8. Liu Zhihua*
9. DNA/RNA-binding protein KIN17 supports esophageal cancer progression via resolving noncanonical STING activation induced by R-loop. Signal Transduction and Targeted Therapy. 10(1):256. 2025.8. Q1, IF=52.7. Liu Zhihua*
10. OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition. Proc Natl Acad Sci USA. 121(19):e2315348121. 2024.5. Q1, IF=9.4. Liu Zhihua*
注：Q1 为期刊分区，IF 为影响因子，* 表示通讯作者
